Sanofi-Aventis and Lilly in Cialis marketing pact

Share this article:
Sanofi-Aventis has teamed with Eli Lilly in a collaboration to market erectile-dysfunction drug Cialis (tadalafil) to US urologists. 

According to Lilly spokesperson Lee Lang, the campaign hopes to “educate urologists nationwide by providing direct selling support for 2.5 mg and 5 mg doses, as well as for use on an ‘as needed' basis.” Lang explains the decision, noting Sanofi's “strong market position in urology.”
Sanofi-Aventis spokeswoman Noelle Boyd added, “Our sales force has developed trust among urologists over the years.” Sanofi-Aventis markets Uroxatral (alfuzosin HCI), for benign prostatic hyperplasia (BPH), and Taxotere (docetaxel), a chemotherapy indicated for prostate cancer, to urologists.

The partnership follows FDA approval in January for a once-daily use in 2.5 mg and 5 mg doses.  Cialis is also known as the “36 hour pill” or the “weekend pill,” due to its longer duration of action in patients. 

A spokesperson for Lilly told CNNMoney that the collaboration with Sanofi-Aventis began on March 13.  On the consumer side, Cialis was recently ranked second in the Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests, according to a Manhattan Research study. 
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.